Findings

What do systematic reviews say?

27 questions · 27 findings · 9 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 25.9%GRADE not reported 5 · 18.5%Very low 7 · 25.9%Low 6 · 22.2%Moderate 2 · 7.4%High 0 · 0%

Oral clonazepam (benzodiazepine) vs placebo

Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…

1 finding from 1 review

Pharmacological interventions for pain in patients with temporomandibular disorders 2010 · Cochrane All outcomes
60 days
One participant in the clonazepam group withdrew from the study by Harkins et al 1991 due to severe headache.
1 study · 20 participants
GRADE not reported

Monthly pegloticase vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 8.19 [1.12, 59.71]
1 study · 127 participants
Moderate

Lesinurad 400 mg plus febuxostat CONTINUED vs lesinurad 200 mg plus febuxostat CONTINUED

Withdrawals due to adverse events · participants with tophi in gout

Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 0.98 [0.44, 2.2]
1 study · 129 participants
Low

Lesinurad 400 mg plus febuxostat CROSS vs lesinurad 200 mg plus febuxostat CROSS

Withdrawals due to adverse events · participants with tophi in gout

Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 2.43 [0.51, 11.64]
1 study · 67 participants
Low

Pegloticase every two weeks (biweekly) vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 7.59 [1.04, 55.55]
1 study · 128 participants
Moderate

Intervention not reported

Number of participant withdrawals due to adverse events ‐ not measured · patients with acute gout

The review found no eligible studies for this question.

1 finding from 1 review

Lifestyle interventions for acute gout 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Skim milk enriched with GMP/G600 vs skim milk & lactose powder

Withdrawals due to adverse events · people with chronic gout

Skim milk enriched with GMP/G600 showed no clear difference in participant withdrawals due to adverse events participant and study… compared with skim milk & lactose powder (low certainty).

1 finding from 1 review · compare the 2 reviews

Lifestyle interventions for chronic gout 2013 · Cochrane Headline outcomes only
RR 1.27 [0.53, 3.03]
1 study · 120 participants
Low